By Léon Van Wouwe, Clinical Innovation Director, Volv Global New data from Roche’s Itovebi (inavolisib) combined with Pfizer’s Ibrance…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Progressive Pulmonary Fibrosis (PPF) is a severe clinical condition…
On the occasion of international Rare Disease Day 2025, we are beyond thrilled to host the voice of patient advocate…
By Christopher Rudolf, Volv Global An AI Methodology for Finding Patients with Rare Diseases: Volv Global’s inTrigue Finding patients with…
Volv, supported by Sanofi, and working with Optimum Patient Care, and collaborating with a specialist Consultant Clinician, is performing research…
By Christopher Rudolf, Volv Global Rare disease patients and the journey to diagnosis, treatment, and support For patients with rare…
By Christopher Rudolf, Volv Global Rare disease patients and the journey to diagnosis, treatment, and support For patients with rare…
By Christopher Rudolf, Volv Global Introduction Rare Disease Day highlights the voices, stories, and experiences of millions of people living…